The purpose of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells(DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with Advanced Non-Small-Cell Lung Cancer with bone metastases. Experimental DC was transfected Ad5 vector coding mRNAs including suppressor of cytokine signaling (SOCS) 1, MUC1 and Survivin,are used for DC-based immunotherapy. Based on the results of our previously preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
Affiliated Hospital to Academy of Military Medical Sciences
Beijing, Beijing Municipality, China
objective response rate (CR+PR) as measured by RECIST criteria
Time frame: one month after DC/CIK treatment
number of participants with adverse events
Time frame: 3 days during DC/CIK treatment]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.